Eloxx Pharmaceuticals, Inc.
ELOX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001035354
No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Eloxx Pharmaceuticals, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 32 | 19 | −13 |
| SharesConverted for a 1-for-40 split | 316.7K | 262.0K | −54.7K (−17.3%) |
| Value | $2.14M | $476.7K | −$1.66M (−77.7%) |
New holders (3)
Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 123 | $224 | 0.00% |
| NewSquare Capital LLC | 1 | $2 | 0.00% |
| Royal Bank of Canada | 14 | $0 | 0.00% |
Sold out (16)
Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Bridgeway Capital Management, LLC | 224,900 | $38.0K |
| State Street Corp | 189,959 | $32.0K |
| Bank of New York Mellon Corp | 145,381 | $25.0K |
| Atom Investors LP | 144,116 | $24.0K |
| Renaissance Technologies LLC | 133,500 | $23.0K |
| Vanguard Capital Wealth Advisors | 127,000 | $22.0K |
| Northern Trust Corp | 123,669 | $21.0K |
| Citadel Advisors LLC | 58,622 | $10.0K |
| National Asset Management, Inc. | 38,500 | $7.00K |
| Virtu Financial LLC | 14,931 | $3.00K |
| Jane Street Group, LLC | 18,520 | $3.00K |
| Advisor Group Holdings, Inc. | 12,359 | $2.00K |
| BNP Paribas Arbitrage, SA | 489 | $83 |
| Credit Suisse AG | 5 | $0 |
| National Bank of Canada | 6 | $0 |
| Simplex Trading, LLC | 460 | $0 |